🇺🇸 FDA
Patent

US 6620802

Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist

expired A61KA61K31/00A61K31/56

Quick answer

US patent 6620802 (Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist) held by Corcept Therapeutics Incorporated expires Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Sep 16 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/00, A61K31/56, A61K31/567, A61K31/568